William Blair Weighs in on Axsome Therapeutics, Inc.'s Q1 2023 Earnings (NASDAQ:AXSM)

Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Rating) – Analysts at William Blair boosted their Q1 2023 EPS estimates for Axsome Therapeutics in a note issued to investors on Wednesday, April 20th. William Blair analyst M. Minter now anticipates that the company will earn ($0.20) per share for the quarter, up from their prior estimate of […]

Related Keywords

United States ,William Blair ,Morgan Stanley ,Geode Capital Management ,Axsome Therapeutics Inc ,Zacks Investment Research ,Nuveen Asset Management ,Blackrock Inc ,Bellevue Group ,Nasdaq ,Jefferies Financial Group ,Axsome Therapeutics ,Get Rating ,Financial Group ,Capital Management ,Asset Management ,Nasdaq Axsm ,Axsm ,Medical ,Earnings Estimates ,